Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30960447 | 0.97 | TSHR (0.33) | TSHRCYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL7483422 | 0.94 | TSHR (0.35) | TSHRCYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL25808045 | 0.91 | — | — | |
| SCHEMBL10045110 | 0.91 | CYP2C19 (0.48) | TSHRCYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL946713 | 0.89 | TSHR (0.39) | TSHRCYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL5002508 | 0.88 | — | — | |
| SCHEMBL24631492 | 0.87 | TSHR (0.50) | TSHRCYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL11457836 | 0.87 | — | — | |
| SCHEMBL10045221 | 0.84 | CYP2C19 (0.62) | TSHRCYP2C19ALDH1A1MEN1KMT2A | |
| SCHEMBL1275790 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287009-A1 | AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME | INFINEUM INTERNATIONAL LIMITED (GB) | 2024-08-29 | — | — | US | claimed |
| EP-4410772-A2 | AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME | Infineum International Limited (GB) | 2024-08-07 | — | — | EP | claimed |
| CN-118440229-A | Amine functional monomers and methods of making the same | 英菲诺姆国际有限公司 | 2024-08-06 | — | — | CN | claimed |
| CN-113264898-B | Benzoxazole colorimetric fluorescent probe ZY15 for detecting mercury ions and preparation method and application thereof | 湖北理工学院 | 2022-05-06 | — | — | CN | claimed |
| CN-113264898-A | Benzoxazole colorimetric fluorescent probe ZY15 for detecting mercury ions and preparation method and application thereof | 湖北理工学院 | 2021-08-17 | — | — | CN | claimed |
| US-9944579-B2 | Catalytic hydrogenation process for the synthesis of terminal diols from terminal dialkyl aliphatic esters | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-04-17 | — | — | US | claimed |
| US-20170349514-A1 | CATALYTIC HYDROGENATION PROCESS FOR THE SYNTHESIS OF TERMINAL DIOLS FROM TERMINAL DIALKYL ALIPHATIC ESTERS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-12-07 | — | — | US | claimed |
| WO-2016113758-A1 | CATALYTIC HYDROGENATION PROCESS FOR THE SYNTHESIS OF TERMINAL DIOLS FROM TERMINAL DIALKYL ALIPHATIC ESTERS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-07-21 | — | — | WO | claimed |
| EP-1456152-B1 | TRIMERISATION AND OLIGOMERISATION OF OLEFINS USING A CHROMIUM BASED CATALYST | SASOL TECH PTY LTD (ZA) | 2012-06-13 | — | — | EP | claimed |
| JP-4308015-B2 | — | — | 2009-08-05 | — | — | JP | claimed |
| US-7300904-B2 | Trimerisation and oligomerisation of olefins using a chromium based catalyst | SASOL TECHNOLOGY (PTY) LTD. (ZA) | 2007-11-27 | — | — | US | claimed |
| JP-2005533872-A | — | — | 2005-11-10 | — | — | JP | claimed |
| US-20050131262-A1 | Trimerisation and oligomerisation of olefins using a chromium based catalyst | SASOL TECHNOLOGY (PTY) LTD. (ZA) | 2005-06-16 | — | — | US | claimed |
| EP-1456152-A1 | TRIMERISATION AND OLIGOMERISATION OF OLEFINS USING A CHROMIUM BASED CATALYST | Sasol Technology (Pty) Ltd (ZA) | 2004-09-15 | — | — | EP | claimed |
| WO-2003053890-A1 | TRIMERISATION AND OLIGOMERISATION OF OLEFINS USING A CHROMIUM BASED CATALYST | SASOL TECHNOLOGY (PTY) LTD (ZA) | 2003-07-03 | — | — | WO | claimed |
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4519233-B1 | PROCESS FOR THE HYDROGENATION OF UNSATURATED ESTERS | JOHNSON MATTHEY PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| CN-1021910-C | LANKACIDIN DERIVATIVES AND PRODUCTION THEREOF | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1993-08-25 | — | — | CN | disclosed |
| US-4914206-A | ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0226896-A2 | Lankacidin derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287009-A1 | AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME | AMD1, HNMT, MAT1A | TSHR 4397/4885CYP2C19 3883/4885ALDH1A1 317/4885 |
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, SLC26A3 | TSHR 1602/4885CYP2C19 1797/4885ALDH1A1 3574/4885 |
| US-20170349514-A1 | CATALYTIC HYDROGENATION PROCESS FOR THE SYNTHESIS OF TERMINAL DIOLS FROM TERMINAL DIALKYL ALIPHATIC ESTERS | HACL2, HPD, HAO2 | TSHR 2737/4885CYP2C19 2306/4885ALDH1A1 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.